
|Videos|August 2, 2022
Available Genomic Tests for Clinically Localized Prostate Cancer
Author(s)Stephen J. Freedland, MD
A review of the currently available genomic testing options for patients with clinically localized prostate cancer and the NCCN and AUA/ASTRO recommendations based on risk group.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD
2
CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom
3
FDA grants breakthrough therapy, fast track designations to kidney cancer imaging agent
4
Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy
5











